Showing results (471-480 of 513) with videos related to
Sort By:
Pageof 52
The British Journal of Dermatology|August 10, 2023
Dupilumab significantly improves sleep in adults with atopic dermatitis: results from the 12-week placebo-controlled period of the 24-week phase IV randomized double-blinded placebo-controlled DUPISTAD studyJoseph F Merola, Albert S Chiou, Emmanuel During, et al.Annals of the Rheumatic Diseases|September 11, 2023
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL studyChristopher T Ritchlin, Laura C Coates, Iain B McInnes, et al.JAMA Dermatology|April 29, 2026
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A ReviewSamip Sheth, Joseph F Merola, Brittany N Weber, et al.Nature Reviews. Rheumatology|January 26, 2026
Recommendations for the use of CLASI as an outcome measure in cutaneous lupus erythematosus clinical trialsGrace Lu, Tyler Cepica, Catherine Barbey, et al.The British Journal of Dermatology|May 4, 2019
Developing classification criteria for skin-predominant dermatomyositis: the Delphi processJ S S Concha, S Pena, R G Gaffney, et al.International Microbiology : the Official Journal of the Spanish Society for Microbiology|July 20, 2026
Hidden in the community: poly-clonal spread of KPC- or NDM-producing Klebsiella pneumoniae revealed by whole-genome sequencing in Southeastern BrazilCarlos H Camargo, Taise C D M Barbosa, Amanda Y Yamada, et al.Lancet (London, England)|December 9, 2022
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)Iain B McInnes, Akihiko Asahina, Laura C Coates, et al.RMD Open|March 17, 2022
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studiesChristopher T Ritchlin, Philip J Mease, Wolf-Henning Boehncke, et al.JACC. Cardiovascular Imaging|March 21, 2021
Impaired Coronary Vasodilator Reserve and Adverse Prognosis in Patients With Systemic Inflammatory DisordersBrittany N Weber, Emma Stevens, Lourdes M Perez-Chada, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|May 23, 2026
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findingsRichard B Warren, Melinda Gooderham, Edward Lain, et al.Pageof 52